Source:http://linkedlifedata.com/resource/pubmed/id/21212791
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-3-9
|
| pubmed:abstractText |
We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n=53), RAEB in transformation (RAEB-T, n=29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n=15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n=57) or alternative family donor (n=1). Stem cell source was bone marrow (n=69) or peripheral blood (n=28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1476-5551
|
| pubmed:author |
pubmed-author:BergstraesserEE,
pubmed-author:BieringsMM,
pubmed-author:BordonVV,
pubmed-author:ChybickaAA,
pubmed-author:EWOG-MDS study group,
pubmed-author:FurlanII,
pubmed-author:KorthofE TET,
pubmed-author:LocatelliFF,
pubmed-author:MoerlooseB DBD,
pubmed-author:NöllkePP,
pubmed-author:NiemeyerC MCM,
pubmed-author:O'MarcaighAA,
pubmed-author:PetersCC,
pubmed-author:SchmuggeMM,
pubmed-author:SedlacekPP,
pubmed-author:StarýJJ,
pubmed-author:StrahlCC,
pubmed-author:TrebsAA,
pubmed-author:WojcikDD,
pubmed-author:ZeccaMM,
pubmed-author:de HerediaC DCD,
pubmed-author:van den Heuvel-EibrinkM MMM
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
455-62
|
| pubmed:meshHeading |
pubmed-meshheading:21212791-Adolescent,
pubmed-meshheading:21212791-Adult,
pubmed-meshheading:21212791-Child,
pubmed-meshheading:21212791-Child, Preschool,
pubmed-meshheading:21212791-Disease-Free Survival,
pubmed-meshheading:21212791-Female,
pubmed-meshheading:21212791-Graft vs Host Disease,
pubmed-meshheading:21212791-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:21212791-Humans,
pubmed-meshheading:21212791-Infant,
pubmed-meshheading:21212791-Male,
pubmed-meshheading:21212791-Myelodysplastic Syndromes,
pubmed-meshheading:21212791-Recurrence
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study.
|
| pubmed:affiliation |
Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany. brigitte.strahm@uniklinik-freiburg.de
|
| pubmed:publicationType |
Journal Article
|